Biogen (BIIB) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Biogen · Health Care · ref. ETF XLV · 123 calls · price $221.5
What the company does: Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions.
📈 Biogen (BIIB) stock price
$221.5+67.0% over range
Aug 28, 25low $132.22 · high $221.56Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
68% recommend buying · 19 analysts
📊 JPI status : Biogen is no longer in our current JPI rankings, but appeared in the past (2025, 2022, 2021) — its upside may be behind it. See the stocks picked in 2025 →
🎯 BIIB price target & analyst consensus — price $222
The price target · all analysts combined (19 targets)
Highest target · 1 firm of 19$300+35.4%
Median target · of 19 targets$240+8.4%
Lowest target · 1 firm of 19$150-32.3%
Current price$221.5
Where these 19 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
1474%
$225 ↔ $300
Below
526%
$150 ↔ $215
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $231 (+4.3 %), call made on July 31, 2026, maturing on July 31, 2027 (28 d ago).
The 13 reliable analysts
$240+8.4 %
The 6 other firms
$238+7.2 %
How to read it: the 13 reliable firms are not filtered by optimism — 10 aim above the price, 3 below, hence their $240 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 19 ratings (last 6 months)
Strong Buy00%
Buy1368%
Hold526%
Sell15%
Strong Sell00%
Go deeper on the analysts
🎯 BIIB price target all
All 21 calls, one by one, with our verdict on each firm.
→ See all 21 targets, analyst by analyst💡 The best analysts on BIIB most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in BIIB? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Biogen? The JPI assistant answers using our backtest data.
📈 Biogen fundamentals: valuation, margins & growth › open the full page
P/E 39.2Net margin 8.3 %Revenue growth +3.4 %High P/E
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 30 %
2023
Rev −3%Profit −62%
2024
Rev −2%Profit +41%
2025
Rev +2%Profit −21%
🔎 Detailed analyses
🏛️ Which US Congress members hold Biogen (BIIB)?
4 Congress members have disclosed BIIB buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
✅ Historical analyst reliability on BIIB
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Deutsche Bank ↗ | 88% | +26.1% | 8 |
| Goldman Sachs ↗ | 86% | +31.4% | 7 |
| Citigroup ↗ | 71% | +10.0% | 14 |
| Jefferies ↗ | 67% | +25.1% | 15 |
| Nomura | 60% | +10.6% | 5 |
| Credit Suisse | 58% | +21.9% | 12 |
| B of A Securities ↗ | 57% | +18.8% | 7 |
| JP Morgan ↗ | 50% | +10.3% | 2 |
| Cowen & Co. | 50% | +3.6% | 4 |
| SunTrust Robinson Humphrey | 50% | -4.3% | 4 |
See the other 25 firms
| Cantor Fitzgerald ↗ | 0% | -36.4% | 3 |
| HSBC ↗ | 0% | -34.2% | 2 |
| Guggenheim ↗ | 0% | -13.2% | 3 |
| Atlantic Equities | 0% | -9.6% | 2 |
| Needham ↗ | 14% | -19.1% | 35 |
| Leerink Swann | 20% | -20.8% | 5 |
| Bernstein ↗ | 25% | -15.8% | 4 |
| Wells Fargo ↗ | 25% | -4.5% | 4 |
| HC Wainwright & Co. ↗ | 27% | -4.6% | 22 |
| Oppenheimer ↗ | 32% | -6.3% | 22 |
| Argus Research ↗ | 33% | -20.3% | 3 |
| Raymond James ↗ | 33% | -11.6% | 3 |
| BMO Capital ↗ | 33% | -10.0% | 12 |
| Piper Sandler ↗ | 33% | -6.4% | 9 |
| Mizuho ↗ | 33% | -4.8% | 9 |
| Scotiabank ↗ | 33% | -3.4% | 3 |
| RBC Capital ↗ | 33% | -0.6% | 30 |
| Barclays ↗ | 33% | +3.2% | 6 |
| Morgan Stanley ↗ | 34% | -3.1% | 47 |
| Baird ↗ | 36% | -8.0% | 11 |
| UBS ↗ | 38% | -3.3% | 8 |
| Canaccord Genuity ↗ | 43% | +10.1% | 14 |
| Truist Securities ↗ | 45% | -2.4% | 11 |
| SVB Leerink | 45% | +0.3% | 11 |
| Stifel ↗ | 45% | +10.7% | 11 |
📊 What $1,000 invested in Biogen would be worth › open the full page
In short — $1,000 invested in Biogen 10 years ago would be worth $705 today, i.e. -3%/yr on average. Best year: 2022 (+15%), worst: 2024 (-41%). Price performance, excluding dividends.
If I'd invested $1,000 in Biogen
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,413 | +41% |
| 3 years ago | $780 | -22% |
| 5 years ago | $882 | -12% |
Return by year (Biogen)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +23% | $1,228 (+23%) |
| 2025 | +15% | $1,413 (+41%) |
| 2024 | -41% | $835 (-17%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Biogen
Loading news…
📋 All analyst calls on BIIB
Filtered on — · ✕ show all
RBC Capital ↗
Aug 25, 26
▲ Outperform · 🎯$260
Price at call : $221.07 — upside +18%
Today : $221.5 — upside +17%
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 25, 27
matures : Aug 25, 27
Wolfe Research ↗
Aug 13, 26
▲ Outperform · 🎯$300
Price at call : $209.83 — upside +43%
Today : $221.5 — upside +35%
🎯 on BIIB : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Aug 13, 27
matures : Aug 13, 27
▲ Outperform · 🎯$241
Price at call : $206.63 — upside +17%
Today : $221.5 — upside +9%
🎯 on BIIB : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Aug 4, 27
matures : Aug 4, 27
■ Neutral neutral · not a buy · 🎯$215
Price at call : $208.45 — gap to target +3%
Today : $221.5 — gap to target -3%
🎯 on BIIB : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
▲ Buy · 🎯$240
Price at call : $202.95 — upside +18%
Today : $221.5 — upside +8%
🎯 on BIIB : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
HC Wainwright & Co. ↗
Jul 30, 26
▲ Buy · 🎯$251
Price at call : $202.95 — upside +24%
Today : $221.5 — upside +13%
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
Morgan Stanley ↗
Jul 30, 26
■ Equal-Weight neutral · not a buy · 🎯$231
Price at call : $202.95 — gap to target +14%
Today : $221.5 — gap to target +4%
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
RBC Capital ↗
Jul 30, 26
▲ Outperform · 🎯$240
Price at call : $202.95 — upside +18%
Today : $221.5 — upside +8%
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
See the other 115 calls, newest to oldest
Canaccord Genuity ↗
Jul 30, 26
▲ Buy · 🎯$248
Price at call : $202.95 — upside +22%
Today : $221.5 — upside +12%
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
▲ Buy · 🎯$225
Price at call : $202.95 — upside +11%
Today : $221.5 — upside +2%
🎯 on BIIB : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
■ Neutral neutral · not a buy · 🎯$215
Price at call : $202.95 — gap to target +6%
Today : $221.5 — gap to target -3%
🎯 on BIIB : no call matured yet · 📊 on Health : 42.9% · -6.3% (7 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
■ Equal-Weight neutral · not a buy · 🎯$200
Price at call : $209.23 — gap to target -4%
Today : $221.5 — gap to target -10%
🎯 on BIIB : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
Guggenheim ↗
Jul 21, 26
▲ Buy · 🎯$280
Price at call : $197.74 — upside +42%
Today : $221.5 — upside +26%
🎯 on BIIB : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jul 21, 27
matures : Jul 21, 27
B of A Securities ↗
Jul 21, 26
■ Neutral neutral · not a buy · 🎯$215
Price at call : $203.16 — gap to target +6%
Today : $221.5 — gap to target -3%
🎯 on BIIB : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jul 21, 27
matures : Jul 21, 27
Truist Securities ↗
Jul 13, 26
▲ Buy · 🎯$235
Price at call : $209.03 — upside +12%
Today : $221.5 — upside +6%
🎯 on BIIB : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
Morgan Stanley ↗
Jul 8, 26
■ Equal-Weight neutral · not a buy · 🎯$222
Price at call : $198.91 — gap to target +12%
Today : $221.5 — gap to target +0%
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
RBC Capital ↗
Jul 7, 26
▲ Outperform · 🎯$242
Price at call : $200.36 — upside +21%
Today : $221.5 — upside +9%
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
▲ Buy · 🎯$256
Price at call : $216.63 — upside +18%
Today : $221.5 — upside +16%
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Jun 29, 27
matures : Jun 29, 27
Morgan Stanley ↗
Jun 18, 26
■ Equal-Weight neutral · not a buy · 🎯$224
Price at call : $196.58 — gap to target +14%
Today : $221.5 — gap to target +1%
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jun 18, 27
matures : Jun 18, 27
▲ Outperform · 🎯$221
Price at call : $195.61 — upside +13%
Today : $221.5 — upside -0%
🎯 on BIIB : no call matured yet · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Jun 15, 27
matures : Jun 15, 27
▲ Buy · 🎯$255
Price at call : $192.62 — upside +32%
Today : $221.5 — upside +15%
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Jun 8, 27
matures : Jun 8, 27
RBC Capital ↗
May 27, 26
▲ Outperform · 🎯$227
Price at call : $196.39 — upside +16%
Today : $221.5 — upside +2%
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 27, 27
matures : May 27, 27
Piper Sandler ↗
May 15, 26
▲ Overweight · 🎯$225
Price at call : $191.91 — upside +17%
Today : $221.5 — upside +2%
🎯 on BIIB : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : May 15, 27
matures : May 15, 27
■ Neutral neutral · not a buy · 🎯$200
Price at call : $187.21 — gap to target +7%
Today : $221.5 — gap to target -10%
🎯 on BIIB : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
Morgan Stanley ↗
Apr 30, 26
■ Equal-Weight neutral · not a buy · 🎯$206
Price at call : $187.06 — gap to target +10%
Today : $221.5 — gap to target -7%
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 30, 27
matures : Apr 30, 27
RBC Capital ↗
Apr 30, 26
▲ Outperform · 🎯$222
Price at call : $187.06 — upside +19%
Today : $221.5 — upside +0%
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Apr 30, 27
matures : Apr 30, 27
Guggenheim ↗
Apr 30, 26
▲ Buy · 🎯$260
Price at call : $187.06 — upside +39%
Today : $221.5 — upside +17%
🎯 on BIIB : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Apr 30, 27
matures : Apr 30, 27
■ Neutral neutral · not a buy · 🎯$196
Price at call : $189.28 — gap to target +4%
Today : $221.5 — gap to target -12%
🎯 on BIIB : no call matured yet · 📊 on Health : 42.9% · -6.3% (7 calls)
in progress (365j)
matures : Apr 30, 27
matures : Apr 30, 27
▲ Buy · 🎯$225
Price at call : $190.07 — upside +18%
Today : $221.5 — upside +2%
🎯 on BIIB : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Apr 22, 27
matures : Apr 22, 27
Wells Fargo ↗
Apr 20, 26
▲ Overweight · 🎯$250
Price at call : $185.95 — upside +34%
Today : $221.5 — upside +13%
🎯 on BIIB : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Apr 20, 27
matures : Apr 20, 27
Piper Sandler ↗
Apr 14, 26
▲ Overweight · 🎯$214
Price at call : $178.96 — upside +20%
Today : $221.5 — upside -3%
🎯 on BIIB : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Apr 14, 27
matures : Apr 14, 27
■ Neutral neutral · not a buy · 🎯$190
Price at call : $178.96 — gap to target +6%
Today : $221.5 — gap to target -14%
🎯 on BIIB : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
Truist Securities ↗
Apr 13, 26
■ Hold neutral · not a buy · 🎯$189
Price at call : $178.96 — gap to target +6%
Today : $221.5 — gap to target -15%
🎯 on BIIB : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
Morgan Stanley ↗
Apr 10, 26
■ Equal-Weight neutral · not a buy · 🎯$200
Price at call : $176.37 — gap to target +13%
Today : $221.5 — gap to target -10%
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 10, 27
matures : Apr 10, 27
HC Wainwright & Co. ↗
Apr 2, 26
▲ Buy · 🎯$237
Price at call : $177.34 — upside +34%
Today : $221.5 — upside +7%
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Apr 2, 27
matures : Apr 2, 27
Canaccord Genuity ↗
Apr 1, 26
▲ Buy · 🎯$245
Price at call : $177.34 — upside +38%
Today : $221.5 — upside +11%
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Apr 1, 27
matures : Apr 1, 27
Oppenheimer ↗
Apr 1, 26
▲ Outperform · 🎯$275
Price at call : $177.34 — upside +55%
Today : $221.5 — upside +24%
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
in progress (365j)
matures : Apr 1, 27
matures : Apr 1, 27
▼ Reduce · 🎯$150
Price at call : $182.31 — upside -18%
Today : $221.5 — upside -32%
🎯 on BIIB : no call matured yet · 📊 on Health : 53.6% · +1.4% (28 calls)
in progress (365j)
matures : Mar 17, 27
matures : Mar 17, 27
Freedom Broker
Feb 23, 26
■ Hold neutral · not a buy · 🎯$185
Price at call : $196.34 — gap to target -6%
Today : $221.5 — gap to target -16%
🎯 on BIIB : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Feb 23, 27
matures : Feb 23, 27
■ Equal-Weight neutral · not a buy · 🎯$185
Price at call : $196.34 — gap to target -6%
Today : $221.5 — gap to target -16%
🎯 on BIIB : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
■ Neutral neutral · not a buy · 🎯$187
Price at call : $191.2 — gap to target -2%
Today : $221.5 — gap to target -16%
🎯 on BIIB : no call matured yet · 📊 on Health : 42.9% · -6.3% (7 calls)
in progress (365j)
matures : Feb 10, 27
matures : Feb 10, 27
■ Neutral neutral · not a buy · 🎯$230
Price at call : $188.99 — gap to target +22%
Today : $221.5 — gap to target +4%
🎯 on BIIB : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
Canaccord Genuity ↗
Feb 9, 26
▲ Buy · 🎯$230
Price at call : $188.99 — upside +22%
Today : $221.5 — upside +4%
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
BMO Capital ↗
Feb 9, 26
■ Market Perform neutral · not a buy · 🎯$196
Price at call : $188.99 — gap to target +4%
Today : $221.5 — gap to target -12%
🎯 on BIIB : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
▲ Buy · 🎯$215
Price at call : $188.99 — upside +14%
Today : $221.5 — upside -3%
🎯 on BIIB : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
■ Neutral neutral · not a buy · 🎯$215
Price at call : $188.99 — gap to target +14%
Today : $221.5 — gap to target -3%
🎯 on BIIB : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
RBC Capital ↗
Feb 9, 26
▲ Outperform · 🎯$233
Price at call : $188.99 — upside +23%
Today : $221.5 — upside +5%
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
Guggenheim ↗
Feb 9, 26
▲ Buy · 🎯$246
Price at call : $188.99 — upside +30%
Today : $221.5 — upside +11%
🎯 on BIIB : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
Wells Fargo ↗
Feb 9, 26
■ Equal-Weight neutral · not a buy · 🎯$200
Price at call : $193.81 — gap to target +3%
Today : $221.5 — gap to target -10%
🎯 on BIIB : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
Truist Securities ↗
Feb 9, 26
■ Hold neutral · not a buy · 🎯$193
Price at call : $193.81 — gap to target -0%
Today : $221.5 — gap to target -13%
🎯 on BIIB : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
HC Wainwright & Co. ↗
Feb 9, 26
▲ Buy · 🎯$228
Price at call : $193.81 — upside +18%
Today : $221.5 — upside +3%
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Feb 9, 27
matures : Feb 9, 27
RBC Capital ↗
Aug 1, 25
▲ Outperform · 🎯$219
Price at call : $132.2 — upside +66%
Today : $221.5 — upside -1%
Expected +66% · Actual +53% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+52.7%
stock +53% · XLV +22%
matured Aug 1, 26
HC Wainwright & Co. ↗
Aug 1, 25
▲ Buy · 🎯$194
Price at call : $131.95 — upside +47%
Today : $221.5 — upside -12%
Expected +47% · Actual +53% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+52.9%
stock +53% · XLV +24%
matured Aug 1, 26
RBC Capital ↗
Jul 7, 25
▲ Outperform · 🎯$208
Price at call : $134.46 — upside +55%
Today : $221.5 — upside -6%
Expected +55% · Actual +49% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+49.0%
stock +49% · XLV +20%
matured Jul 7, 26
RBC Capital ↗
Jun 27, 25
▲ Outperform · 🎯$213
Price at call : $126.08 — upside +69%
Today : $221.5 — upside -4%
Expected +69% · Actual +72% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+71.8%
stock +72% · XLV +20%
matured Jun 27, 26
HC Wainwright & Co. ↗
Jun 26, 25
▲ Buy · 🎯$187
Price at call : $126.92 — upside +47%
Today : $221.5 — upside -16%
Expected +47% · Actual +70% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+70.2%
stock +70% · XLV +19%
matured Jun 26, 26
RBC Capital ↗
Jun 25, 25
▲ Outperform · 🎯$213
Price at call : $126.92 — upside +68%
Today : $221.5 — upside -4%
Expected +68% · Actual +70% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+70.2%
stock +70% · XLV +19%
matured Jun 25, 26
RBC Capital ↗
May 2, 25
▲ Outperform · 🎯$205
Price at call : $121.8 — upside +68%
Today : $221.5 — upside -7%
Expected +68% · Actual +54% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+53.7%
stock +54% · XLV +5%
matured May 2, 26
Canaccord Genuity ↗
May 2, 25
▲ Buy · 🎯$220
Price at call : $121.8 — upside +81%
Today : $221.5 — upside -1%
Expected +81% · Actual +54% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+53.7%
stock +54% · XLV +5%
matured May 2, 26
HC Wainwright & Co. ↗
May 2, 25
▲ Buy · 🎯$187
Price at call : $123.53 — upside +51%
Today : $221.5 — upside -16%
Expected +51% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+51.5%
stock +52% · XLV +4%
matured May 2, 26
RBC Capital ↗
Apr 22, 25
▲ Outperform · 🎯$225
Price at call : $118.17 — upside +90%
Today : $221.5 — upside +2%
Expected +90% · Actual +59% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+59.0%
stock +59% · XLV +8%
matured Apr 22, 26
RBC Capital ↗
Feb 13, 25
▲ Outperform · 🎯$225
Price at call : $137.33 — upside +64%
Today : $221.5 — upside +2%
Expected +64% · Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+42.4%
stock +42% · XLV +9%
matured Feb 13, 26
HC Wainwright & Co. ↗
Feb 13, 25
▲ Buy · 🎯$241
Price at call : $138.45 — upside +74%
Today : $221.5 — upside +9%
Expected +74% · Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+41.9%
stock +42% · XLV +8%
matured Feb 13, 26
Canaccord Genuity ↗
Feb 13, 25
▲ Buy · 🎯$265
Price at call : $138.45 — upside +91%
Today : $221.5 — upside +20%
Expected +91% · Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+41.9%
stock +42% · XLV +8%
matured Feb 13, 26
Oppenheimer ↗
Oct 31, 24
▲ Outperform · 🎯$255
Price at call : $173.79 — upside +47%
Today : $221.5 — upside +15%
Expected +47% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-12.9%
stock -13% · XLV -2%
matured Oct 31, 25
HC Wainwright & Co. ↗
Oct 31, 24
▲ Buy · 🎯$300
Price at call : $173.79 — upside +73%
Today : $221.5 — upside +35%
Expected +73% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-12.9%
stock -13% · XLV -2%
matured Oct 31, 25
▲ Buy · 🎯$270
Price at call : $174 — upside +55%
Today : $221.5 — upside +22%
Expected +55% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-11.3%
stock -11% · XLV -2%
matured Oct 31, 25
▲ Buy · 🎯$270
Price at call : $181.18 — upside +49%
Today : $221.5 — upside +22%
Expected +49% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-17.4%
stock -17% · XLV -3%
matured Oct 30, 25
RBC Capital ↗
Oct 4, 24
▲ Outperform · 🎯$269
Price at call : $183.34 — upside +47%
Today : $221.5 — upside +21%
Expected +47% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
-16.0%
stock -16% · XLV -5%
matured Oct 4, 25
▲ Buy · 🎯$285
Price at call : $189.07 — upside +51%
Today : $221.5 — upside +29%
Expected +51% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-28.2%
stock -28% · XLV -12%
matured Sep 24, 25
RBC Capital ↗
Sep 19, 24
▲ Outperform · 🎯$292
Price at call : $201.44 — upside +45%
Today : $221.5 — upside +32%
Expected +45% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
-29.3%
stock -29% · XLV -12%
matured Sep 19, 25
▲ Buy · 🎯$285
Price at call : $204.95 — upside +39%
Today : $221.5 — upside +29%
Expected +39% · Actual -32% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-31.7%
stock -32% · XLV -12%
matured Sep 4, 25
▲ Buy · 🎯$285
Price at call : $206.06 — upside +38%
Today : $221.5 — upside +29%
Expected +38% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-32.6%
stock -33% · XLV -11%
matured Aug 19, 25
▲ Buy · 🎯$285
Price at call : $198.39 — upside +44%
Today : $221.5 — upside +29%
Expected +44% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-33.0%
stock -33% · XLV -10%
matured Aug 5, 25
RBC Capital ↗
Aug 2, 24
▲ Outperform · 🎯$292
Price at call : $198.39 — upside +47%
Today : $221.5 — upside +32%
Expected +47% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
-33.4%
stock -33% · XLV -9%
matured Aug 2, 25
▲ Buy · 🎯$288
Price at call : $210.7 — upside +37%
Today : $221.5 — upside +30%
Expected +37% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-37.4%
stock -37% · XLV -13%
matured Aug 1, 25
▲ Buy · 🎯$294
Price at call : $214.43 — upside +37%
Today : $221.5 — upside +33%
Expected +37% · Actual -40% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-39.7%
stock -40% · XLV -10%
matured Jul 26, 25
▲ Buy · 🎯$294
Price at call : $231.82 — upside +27%
Today : $221.5 — upside +33%
Expected +27% · Actual -46% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-45.8%
stock -46% · XLV -8%
matured Jun 28, 25
RBC Capital ↗
Jun 27, 24
▲ Outperform · 🎯$317
Price at call : $231.82 — upside +37%
Today : $221.5 — upside +43%
Expected +37% · Actual -46% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
-45.8%
stock -46% · XLV -8%
matured Jun 27, 25
RBC Capital ↗
Jun 26, 24
▲ Outperform · 🎯$317
Price at call : $228.72 — upside +39%
Today : $221.5 — upside +43%
Expected +39% · Actual -45% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 58% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
-44.9%
stock -45% · XLV -8%
matured Jun 26, 25
HC Wainwright & Co. ↗
May 23, 24
▲ Buy · 🎯$300
Price at call : $218.06 — upside +38%
Today : $221.5 — upside +35%
Expected +38% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-42.3%
stock -42% · XLV -10%
matured May 23, 25
▲ Buy · 🎯$294
Price at call : $218.06 — upside +35%
Today : $221.5 — upside +33%
Expected +35% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-42.3%
stock -42% · XLV -10%
matured May 22, 25
Oppenheimer ↗
Apr 29, 24
▲ Outperform · 🎯$270
Price at call : $214.82 — upside +26%
Today : $221.5 — upside +22%
Expected +26% · Actual -44% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-43.6%
stock -44% · XLV +0%
matured Apr 29, 25
HC Wainwright & Co. ↗
Apr 25, 24
▲ Buy · 🎯$300
Price at call : $202.46 — upside +48%
Today : $221.5 — upside +35%
Expected +48% · Actual -41% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-41.3%
stock -41% · XLV -1%
matured Apr 25, 25
▲ Buy · 🎯$294
Price at call : $202.46 — upside +45%
Today : $221.5 — upside +33%
Expected +45% · Actual -41% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-41.3%
stock -41% · XLV -1%
matured Apr 25, 25
▲ Buy · 🎯$294
Price at call : $201.99 — upside +46%
Today : $221.5 — upside +33%
Expected +46% · Actual -41% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 0% (12 calls matureds) · 📊 on Health : 50.3% · +4.1% (155 calls)
-40.8%
stock -41% · XLV -2%
matured Apr 24, 25
Oppenheimer ↗
Apr 19, 24
▲ Outperform · 🎯$270
Price at call : $194.11 — upside +39%
Today : $221.5 — upside +22%
Expected +39% · Actual -40% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-40.0%
stock -40% · XLV -5%
matured Apr 19, 25
Canaccord Genuity ↗
Feb 20, 24
▲ Buy · 🎯$305
Price at call : $221.11 — upside +38%
Today : $221.5 — upside +38%
Expected +38% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-38.0%
stock -38% · XLV +1%
matured Feb 19, 25
Oppenheimer ↗
Feb 14, 24
▲ Outperform · 🎯$290
Price at call : $223.35 — upside +30%
Today : $221.5 — upside +31%
Expected +30% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-38.5%
stock -39% · XLV -0%
matured Feb 13, 25
HC Wainwright & Co. ↗
Feb 14, 24
▲ Buy · 🎯$325
Price at call : $220.74 — upside +47%
Today : $221.5 — upside +47%
Expected +47% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-37.3%
stock -37% · XLV +2%
matured Feb 13, 25
Oppenheimer ↗
Jan 30, 24
▲ Outperform · 🎯$295
Price at call : $246.66 — upside +20%
Today : $221.5 — upside +33%
Expected +20% · Actual -41% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-40.7%
stock -41% · XLV +5%
matured Jan 29, 25
Oppenheimer ↗
Dec 18, 23
▲ Outperform · 🎯$295
Price at call : $251.69 — upside +17%
Today : $221.5 — upside +33%
Expected +17% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-41.7%
stock -42% · XLV +2%
matured Dec 17, 24
Morgan Stanley ↗
Nov 10, 23
▲ Overweight · 🎯$373
Price at call : $224.79 — upside +66%
Today : $221.5 — upside +68%
Expected +66% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-23.5%
stock -23% · XLV +18%
matured Nov 9, 24
Morgan Stanley ↗
Oct 11, 23
▲ Overweight · 🎯$361
Price at call : $266.52 — upside +35%
Today : $221.5 — upside +63%
Expected +35% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-29.2%
stock -29% · XLV +17%
matured Oct 10, 24
Morgan Stanley ↗
Sep 5, 23
▲ Overweight · 🎯$381
Price at call : $263.72 — upside +44%
Today : $221.5 — upside +72%
Expected +44% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-23.5%
stock -23% · XLV +18%
matured Sep 4, 24
Oppenheimer ↗
Aug 7, 23
▲ Outperform · 🎯$290
Price at call : $274.14 — upside +6%
Today : $221.5 — upside +31%
Expected +6% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-27.1%
stock -27% · XLV +8%
matured Aug 6, 24
Morgan Stanley ↗
Jul 26, 23
▲ Overweight · 🎯$363
Price at call : $262.79 — upside +38%
Today : $221.5 — upside +64%
Expected +38% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-19.6%
stock -20% · XLV +11%
matured Jul 25, 24
HC Wainwright & Co. ↗
Jul 26, 23
▲ Buy · 🎯$325
Price at call : $265.25 — upside +23%
Today : $221.5 — upside +47%
Expected +23% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-14.2%
stock -14% · XLV +10%
matured Jul 25, 24
Morgan Stanley ↗
Jul 11, 23
▲ Overweight · 🎯$355
Price at call : $279.84 — upside +27%
Today : $221.5 — upside +60%
Expected +27% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-16.8%
stock -17% · XLV +13%
matured Jul 10, 24
HC Wainwright & Co. ↗
Jul 7, 23
▲ Buy · 🎯$325
Price at call : $275.07 — upside +18%
Today : $221.5 — upside +47%
Expected +18% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-17.1%
stock -17% · XLV +12%
matured Jul 6, 24
Oppenheimer ↗
Jun 12, 23
▲ Outperform · 🎯$360
Price at call : $313.41 — upside +15%
Today : $221.5 — upside +63%
Expected +15% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-28.0%
stock -28% · XLV +12%
matured Jun 11, 24
Canaccord Genuity ↗
Jun 12, 23
▲ Buy · 🎯$350
Price at call : $313.41 — upside +12%
Today : $221.5 — upside +58%
Expected +12% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-28.0%
stock -28% · XLV +12%
matured Jun 11, 24
HC Wainwright & Co. ↗
Jun 12, 23
▲ Buy · 🎯$325
Price at call : $313.41 — upside +4%
Today : $221.5 — upside +47%
Expected +4% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-28.0%
stock -28% · XLV +12%
matured Jun 11, 24
Canaccord Genuity ↗
Apr 26, 23
▲ Buy · 🎯$330
Price at call : $293.72 — upside +12%
Today : $221.5 — upside +49%
Expected +12% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-28.9%
stock -29% · XLV +6%
matured Apr 25, 24
Oppenheimer ↗
Apr 26, 23
▲ Outperform · 🎯$325
Price at call : $288.04 — upside +13%
Today : $221.5 — upside +47%
Expected +13% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-29.7%
stock -30% · XLV +6%
matured Apr 25, 24
HC Wainwright & Co. ↗
Apr 26, 23
▲ Buy · 🎯$325
Price at call : $288.04 — upside +13%
Today : $221.5 — upside +47%
Expected +13% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-29.7%
stock -30% · XLV +6%
matured Apr 25, 24
Morgan Stanley ↗
Apr 26, 23
▲ Overweight · 🎯$371
Price at call : $288.04 — upside +29%
Today : $221.5 — upside +67%
Expected +29% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-29.7%
stock -30% · XLV +6%
matured Apr 25, 24
Morgan Stanley ↗
Apr 12, 23
▲ Overweight · 🎯$349
Price at call : $289.7 — upside +20%
Today : $221.5 — upside +58%
Expected +20% · Actual -32% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-31.6%
stock -32% · XLV +2%
matured Apr 11, 24
Morgan Stanley ↗
Feb 16, 23
▲ Overweight · 🎯$351
Price at call : $271.53 — upside +29%
Today : $221.5 — upside +58%
Expected +29% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-19.3%
stock -19% · XLV +11%
matured Feb 16, 24
Oppenheimer ↗
Feb 16, 23
▲ Outperform · 🎯$310
Price at call : $271.53 — upside +14%
Today : $221.5 — upside +40%
Expected +14% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-19.3%
stock -19% · XLV +11%
matured Feb 16, 24
Morgan Stanley ↗
Jan 24, 23
▲ Overweight · 🎯$345
Price at call : $291.88 — upside +18%
Today : $221.5 — upside +56%
Expected +18% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-15.3%
stock -15% · XLV +4%
matured Jan 24, 24
Oppenheimer ↗
Nov 14, 22
▲ Outperform · 🎯$315
Price at call : $299.06 — upside +5%
Today : $221.5 — upside +42%
Expected +5% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
-24.7%
stock -25% · XLV -4%
matured Nov 14, 23
Morgan Stanley ↗
Oct 26, 22
▲ Overweight · 🎯$325
Price at call : $277.87 — upside +17%
Today : $221.5 — upside +47%
Expected +17% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-15.6%
stock -16% · XLV -6%
matured Oct 26, 23
Morgan Stanley ↗
Oct 13, 22
▲ Overweight · 🎯$321
Price at call : $269.94 — upside +19%
Today : $221.5 — upside +45%
Expected +19% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-2.9%
stock -3% · XLV +4%
matured Oct 13, 23
Oppenheimer ↗
Jul 18, 22
▲ Outperform · 🎯$230
Price at call : $220.26 — upside +4%
Today : $221.5 — upside +4%
Expected +4% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 44.1% · +0.6% (220 calls)
+25.7%
stock +26% · XLV +2%
matured Jul 18, 23
Morgan Stanley ↗
May 4, 22
▲ Overweight · 🎯$285
Price at call : $201.18 — upside +42%
Today : $221.5 — upside +29%
Expected +42% · Actual +58% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 8% (12 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
+58.1%
stock +58% · XLV +3%
matured May 4, 23
Canaccord Genuity ↗
Feb 7, 22
▲ Buy · 🎯$305
Price at call : $221.3 — upside +38%
Today : $221.5 — upside +38%
Expected +38% · Actual +32% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+31.7%
stock +32% · XLV +1%
matured Feb 7, 23
Canaccord Genuity ↗
Jul 27, 21
▲ Buy · 🎯$423
Price at call : $334.18 — upside +27%
Today : $221.5 — upside +91%
Expected +27% · Actual -36% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-35.9%
stock -36% · XLV +1%
matured Jul 27, 22
Canaccord Genuity ↗
Apr 24, 20
▲ Buy · 🎯$350
Price at call : $303.24 — upside +15%
Today : $221.5 — upside +58%
Expected +15% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-11.1%
stock -11% · XLV +21%
matured Apr 24, 21
Canaccord Genuity ↗
Jan 27, 20
▲ Buy · 🎯$360
Price at call : $281.14 — upside +28%
Today : $221.5 — upside +63%
Expected +28% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-3.4%
stock -3% · XLV +16%
matured Jan 26, 21
Canaccord Genuity ↗
Jul 23, 18
▲ Buy · 🎯$396
Price at call : $358.13 — upside +11%
Today : $221.5 — upside +79%
Expected +11% · Actual -32% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-31.9%
stock -32% · XLV +6%
matured Jul 23, 19
Canaccord Genuity ↗
May 31, 18
▲ Buy
Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-25.4%
stock -25% · XLV +6%
matured May 31, 19
Canaccord Genuity ↗
Apr 1, 13
▲ Buy · 🎯$206
Price at call : $198.19 — upside +4%
Today : $221.5 — upside -7%
Expected +4% · Actual +56% · Reason (≥ +15%) : ✓ Yes
🎯 on BIIB : 33% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+56.3%
stock +56% · XLV +26%
matured Apr 1, 14
Frequently asked questions
Should I buy Biogen stock?
This isn't buy advice. For Biogen, the analyst consensus is "Buy", with an average price target of $240 (+8% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 88% of the time (8 calls tracked on Biogen). We show the numbers — you decide.
Is it too late to buy Biogen? How high can it go?
The most bullish analyst target on Biogen is $300 (+35% above today's price); the average is $240. That's the upside they see. Check how reliable those analysts have actually been on Biogen on our site before trusting it.
Is Biogen still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 35 analysts have a real record on Biogen, the best hitting 88% over 8 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Biogen? The case for and against
The arguments for and against, one by one, from the numbers: why invest in BIIB (and why hesitate).
What has Biogen's past performance been?
Historical returns and a "how much if I had invested" calculator: BIIB performance & returns.
What is the best month to buy BIIB?
The 12 months ranked by the stock's past returns: best & worst month to buy BIIB.
Are insiders buying BIIB stock?
Executives' and large holders' buys and sells, decoded: insider buying on BIIB.
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX 
LLY